Postmenopausal bleeding is any vaginal bleeding that occurs after 12 consecutive months without a menstrual period — the point that defines menopause. It can be heavy or minimal. It can be bright red or brown spotting. It can occur once or repeatedly. The amount and appearance do not determine whether evaluation is needed — the fact that it occurred after confirmed menopause does.
The reason postmenopausal bleeding always warrants evaluation is that endometrial cancer — cancer of the uterine lining — presents as postmenopausal bleeding in the majority of cases. Approximately 10 percent of women with postmenopausal bleeding have endometrial cancer. That means 90 percent have a benign cause — atrophy, polyps, fibroids, hormonal changes. But the only way to know which group a woman is in is through clinical evaluation, not through observation. And endometrial cancer found at Stage I — when it is presenting as postmenopausal bleeding without other symptoms — has a five-year survival rate above 95 percent. The same cancer found later has a dramatically worse prognosis.
Endometrial Atrophy — Most Common Benign Cause
Estrogen deficiency in postmenopause thins the uterine lining to a fragile, atrophic state that can bleed spontaneously from trivial trauma or friction. Atrophic endometrium is the most common cause of postmenopausal bleeding overall — accounting for approximately 60 to 80 percent of cases in some series. It is benign and managed with local or systemic estrogen therapy. However, atrophic endometrium and endometrial cancer can coexist, and the diagnosis of atrophy does not exclude cancer without specific endometrial evaluation when the clinical picture warrants it.
Endometrial Polyps
Endometrial polyps are benign outgrowths of the uterine lining that are extremely common in postmenopausal women. They produce irregular vaginal bleeding and are identified on transvaginal ultrasound, sonohysterography, or hysteroscopy. Most endometrial polyps are benign, but a small percentage contain atypical cells or early malignancy, and most are removed when identified for both diagnostic and symptomatic purposes. Polypectomy is performed hysteroscopically at Lapeer Women’s Health.
Endometrial Hyperplasia
Endometrial hyperplasia is an overgrowth of the uterine lining driven by estrogen excess — from obesity-related estrogen production, hormone therapy, or other sources — in the absence of adequate progesterone opposition. Without atypia, hyperplasia is managed with progestin therapy. With atypia (atypical endometrial hyperplasia), the risk of coexisting endometrial carcinoma and progression to cancer without treatment is significant enough that hysterectomy is the recommended treatment for most women. Endometrial biopsy identifies hyperplasia and its grade.
Endometrial Cancer
Endometrial cancer is the most common gynecologic malignancy in the United States. It presents as postmenopausal bleeding in the large majority of cases — which is why postmenopausal bleeding is the most important early warning sign and why evaluation must not be delayed. Risk factors include obesity, diabetes, hypertension, unopposed estrogen exposure, nulliparity, late menopause, and Lynch syndrome. Early-stage endometrial cancer is highly curable with hysterectomy. When postmenopausal bleeding is evaluated promptly, the majority of endometrial cancers are found at Stage I when treatment is most effective.
Cervical and Vaginal Causes
Cervical polyps, cervical cancer, vaginal atrophy, and vaginal lacerations are non-uterine sources of postmenopausal bleeding that are identified on pelvic examination and Pap test. Cervical cancer presenting as postmenopausal or postcoital bleeding requires prompt evaluation. Vaginal atrophy producing bleeding is a common benign cause that responds to local estrogen therapy.
Hormone Therapy-Related Bleeding
Women taking systemic hormone therapy — particularly combined estrogen-progestin regimens — may experience irregular breakthrough bleeding, especially in the first months of use. Bleeding on hormone therapy that is unexpected, heavy, or persistent warrants evaluation to ensure it reflects hormonal regulation rather than a structural cause.
Any vaginal bleeding after menopause should be evaluated within 2 to 4 weeks. This includes:
- A single episode of spotting, regardless of how minimal
- Brownish discharge that could represent old blood
- Any bleeding occurring months or years after the last menstrual period
- Bleeding after a gynecologic examination in a postmenopausal woman
Pelvic Examination and Cervical Assessment
A complete pelvic examination assesses the cervix, vagina, uterus, and adnexa. Cervical polyps, cervical lesions, vaginal atrophy, and other non-uterine bleeding sources are identified. A Pap test is performed if not current. The examination provides initial clinical context before imaging.
Transvaginal Ultrasound
Transvaginal ultrasound measures the endometrial thickness and assesses the uterine cavity for polyps, fibroids, and other structural abnormalities. In postmenopausal women, an endometrial thickness of 4mm or less is reassuring against endometrial cancer in most clinical contexts — though endometrial biopsy remains appropriate when clinical suspicion warrants it regardless of thickness measurement.
Endometrial Biopsy
Endometrial biopsy — sampling of the uterine lining with a small instrument inserted through the cervix — provides the tissue diagnosis that identifies endometrial cancer, atypical hyperplasia, benign hyperplasia, or atrophy. It is performed in the office without general anesthesia and takes approximately 5 minutes. It is the definitive diagnostic test for postmenopausal bleeding evaluation in most clinical situations.
The most consistent finding in studies of women diagnosed with endometrial cancer is delayed presentation — women who had postmenopausal bleeding for months before seeking evaluation, who attributed it to atrophy or hormonal causes, or who were told by another provider to observe it. The window between postmenopausal bleeding and advanced endometrial cancer is measured in months to years. The evaluation that closes that window is straightforward, available in our office, and typically completed within a single visit.
Dr. Ramona D. Andrei and the team at Lapeer Women’s Health provide prompt evaluation of postmenopausal bleeding at both our Lapeer and Rochester Hills offices. No referral required. Do not wait.
Our team at Lapeer Women’s Health provides prompt, thorough workup at both offices. No referral required.
Schedule a Gynecologic VisitEducational purposes only. Not medical advice. Content reviewed by Dr. Ramona D. Andrei, MD PhD FACOG.
Gynecologic care for women of every age
Lapeer Women’s Health — Rochester Hills
2710 S Rochester Rd, Suite 2
Rochester Hills, MI 48307
Serving patients in Lapeer, Rochester Hills, and surrounding communities throughout Southeast Michigan.